ClinicalTrials.gg
CompletedNCT07314320Updated Jan 2, 2026

A Study to Detect Radioactivity of [14C]-OPC-167832 in Urine and Feces in Healthy Men

A Phase 1 interventional study of [14C]-OPC-167832 in Healthy Volunteers, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 10 months ago, and no results have been posted to the registry.
  • Registered 2 years after the study started (first participant enrolled Nov 2023, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to determine the relative amounts of radioactivity excreted in urine and feces following a single oral dose of [14C]-OPC-167832 in healthy male participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.

Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI) between 18 to 32 kilograms per square meter (kg/m\^2) (inclusive).
  2. In good health as determined by:

    1. Medical history
    2. Physical examination
    3. Serum/urine biochemistry, hematology, and serology tests.
  3. Experience regular bowel movements (i.e., at least 1 every day) for 30 days prior to Day -1.
  4. Agree to remain exclusively in the research unit for the defined period.
  5. Agree to comply with the protocol restrictions and requirements.
  6. Ability to provide written, prior to initiation of any trial-related procedures, and ability, in the opinion of the principal investigator, to comply with all the requirements of the trial.
  7. Male participants and their female partners who commit to remaining abstinent from trial screening through 90 days after the dose of medicinal product (IMP) or utilizing 2 different approved methods of from trial screening through 90 days after the dose of IMP.
  8. Commit to refraining from sperm donation from the screening visit through 90 days after the dose of IMP.

Exclusion criteria

Exclusion Criteria:

  1. abnormality in past medical history, or at the screening physical examination, that in the investigator's or sponsor's opinion may place the participant at risk or interfere with outcome variables including distribution, metabolism, and excretion of drug.
  2. History of drug and/or alcohol abuse within 2 years prior to screening.
  3. History of or current hepatitis or carriers of surface antigen (HBsAg) and/or anti- virus (HCV), or (HIV) antibodies.
  4. History of any significant drug allergy or known or suspected , to any component of the IMP.
  5. Participants having taken OPC-167832 within 30 days prior to screening.
  6. Participants having 5 half-lives or twice the duration of the biological effect, whichever is longer, of any IMP (inclusive of OPC-167832) within 30 days prior to screening.
  7. Participation in a clinical trial involving administration of 14C-labelled compound(s) within the last 12 months prior to screening.
  8. Any participant who, in the opinion of the investigator, should not participate in the trial.

Note: Other protocol-specified inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    [14C]-OPC-167832

    Participants receive a single dose of \[14C\]-OPC-167832, orally, on Day 1.

    Drug: [14C]-OPC-167832

Interventions

06

What researchers measure

Primary outcomes

  1. Cumulative Amount (Microgram Equivalents) of OPC-167832 Excreted in Urine (Ae,u)

    Time frame: Up to Day 31

  2. Cumulative Amount (Microgram Equivalents) of OPC-167832 Excreted in Feces (Ae,f)

    Time frame: Up to Day 31

  3. Percentage of OPC-167832 Dose Excreted in Urine (%fe,u)

    Time frame: Up to Day 31

  4. Percentage of OPC-167832 Dose Excreted in Feces (%fe,f)

    Time frame: Up to Day 31

Secondary outcomes

  1. Maximum (peak) Concentration (Cmax) of Total Radioactivity in Plasma and Whole Blood

    Time frame: Up to Day 31

  2. Time to Maximum (Peak) Concentration (Tmax) of Total Radioactivity in Plasma and Whole Blood

    Time frame: Up to Day 31

  3. Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Observable Concentration (AUCt) of Total Radioactivity in Plasma and Whole Blood

    Time frame: Up to Day 31

  4. Area Under the Concentration-Time Curve From Time Zero to infinity (AUCinfinity) of Total Radioactivity in Plasma and Whole Blood

    Time frame: Up to Day 31

  5. Terminal-phase Elimination Half-life (t1/2,z) of Total Radioactivity in Plasma and Whole Blood

    Time frame: Up to Day 31

  6. Hemocrit Blood to Plasma Concentration Adjusted Ratio

    Time frame: Up to Day 31

  7. Percentage of Metabolite in Plasma With an AUC > 10% of the AUC of Plasma Radioactivity Based on Radiometric Profiling

    Time frame: Up to Day 31

  8. Cmax of OPC-167832

    Time frame: Up to Day 31

  9. Tmax of OPC-167832

    Time frame: Up to Day 31

  10. AUCt of OPC-167832

    Time frame: Up to Day 31

  11. AUCinfinity of OPC-167832

    Time frame: Up to Day 31

  12. t1/2,z of OPC-167832

    Time frame: Up to Day 31

  13. Apparent Clearance (CL/F) of Drug from Plasma Following Extravascular Administration of OPC-167832

    Time frame: Up to Day 31

  14. Percent Radioactivity Excreted in Urine and Feces as Parent and Identified Metabolites From Profiling data

    Time frame: Up to Day 31

  15. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to Day 31

  16. Number of Participants With Potentially Clinically Relevant Changes in Clinical Laboratory Tests

    Time frame: Up to Day 31

  17. Number of Participants With Potentially Clinically Relevant Changes in Vital Signs

    Time frame: Up to Day 31

  18. Number of Participants With Potentially Clinically Relevant Changes in Physical Examinations

    Time frame: Up to Day 31

  19. Number of Participants With Potentially Clinically Relevant Changes in Electrocardiogram (ECG) Parameters

    Time frame: Up to Day 31

07

Study locations

1 site
  • Celerion, Inc
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Dec 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2025
First posted
Jan 2, 2026
StartActual
Nov 20, 2023
Primary completionActual
Dec 27, 2023
CompletionActual
Dec 27, 2023
Last update
Jan 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07314320
Responsible party
Sponsor
First posted
Jan 2, 2026
Start date
Nov 20, 2023
Primary completion
Dec 27, 2023
Completion
Dec 27, 2023
Last update
Jan 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Quabodepistat

Start the discussion